BRIEF-Inventiva announces new compelling data on Odiparcil/IVA336
* INVENTIVA ANNOUNCES NEW COMPELLING DATA ON ODIPARCIL/IVA336 TO BE PRESENTED AT MPS SOCIETY NATIONAL CONFERENCE
ZURICH, April 27 Swiss drugmaker Roche's first-quarter sales rose 4 percent, more than expected, as the biggest maker of oncology medicines was helped by its new cancer immunotherapy Tecentriq and by strong sales of its older drugs.
Sales rose to 12.94 billion Swiss francs ($13.03 billion), Roche said in a statement, compared to the 12.704 billion franc average estimate of analysts in a Reuters poll. The company, which confirmed its 2017 full-year targets, releases earnings details in July.
Sales of Tecentriq hit 113 million francs, more than the 103 million estimate in the Reuters poll, with revenue from mainstay cancer drugs Avastin, Rituxan and Herceptin also beating expectations. ($1 = 0.9932 Swiss francs) (Reporting by John Miller, Editing by Michael Shields)
BOSTON, June 29 The U.S. Internal Revenue Service is probing whether a patient-assistance charity wrongly gave a benefit to its pharmaceutical company donors by returning most of the money they donated as payments for drugs they make, court papers show.
* STALLERGENES GREER ANNOUNCES MATTHIAS VOGT AS CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)